Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Identification of HLA-A0201 restricted epitope of novel cancer/testis antigens VCX/Y and generation of antigen-specific T-cell receptor engineered T cells for treatment of solid tumor malignancies.
Authors
Ke Pan
The University of Texas MD Anderson Cancer Center, Houston, TX
Ke Pan, Cassian Yee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Cell Therapies
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 160)
DOI
10.1200/JCO.2018.36.5_suppl.160
Abstract #
160
Poster Bd #
K2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer.
First Author: Stefan Barisic
Poster
2024 ASCO Genitourinary Cancers Symposium
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2023 ASCO Annual Meeting
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli